Korro Bio, Inc. is pioneering a novel approach to genetic medicine through its proprietary platform, Oligonucleotide Promoted Editing of RNA (OPERA®). This technology leverages the natural process of RNA editing, specifically utilizing the enzyme adenosine deaminase acting on RNA (ADAR), to introduce precise modifications to RNA sequences. By delivering chemically modified RNA oligonucleotides, Korro Bio aims to correct pathogenic variants associated with various diseases, such as alpha-1 antitrypsin deficiency (AATD) and Parkinson's disease. The company’s approach not only focuses on repairing genetic mutations but also on modulating biological pathways, thereby offering potential therapeutic benefits for a range of conditions affecting the liver, central nervous system, and pain management.

Korro Bio's innovative RNA editing technology is characterized by its high specificity and low risk of off-target effects, which are significant advantages over traditional DNA editing methods. The company employs customized high-fidelity oligonucleotides, known as CHORDs™, which are designed to enhance the efficiency and safety of RNA editing. These oligonucleotides are delivered using established methods, such as lipid nanoparticles, ensuring targeted and effective treatment. Additionally, the transient nature of CHORDs™ minimizes immunogenicity risks, allowing for repeated dosing if necessary. Through its advanced understanding of ADAR biology and machine learning optimization, Korro Bio is positioned to develop effective therapies for complex diseases, addressing unmet medical needs in the field of genetic medicine.

United States

Korro Bio was founded to turn extraordinary scientific insights into life-altering new treatments for patients. We harness the body’s natural RNA editing machinery to make precise, single-base RNA edits to modulate protein function, addressing the medical needs of patients. Our mission is to rewrite the future for patients living with debilitating disease by repairing the underlying genetic cause.

Genetic Diseases

Liver Diseases

Lung Diseases

Korro Bio, Inc. 

Alpha-1 Antitrypsin Deficiency

KRRO-110

Severe alpha-1 antitrypsin deficiency

Korro Bio Drug #1

Biologics

Gene Therapy

Ear disease

Sensorineural hearing loss

<p class="font_8">FX-322 is designed to treat the underlying cause of sensorineural hearing loss (SNHL) by regenerating hair cells through activation of progenitor cells already present in the cochlea.</p>

Korro Bio, Inc.

Company Details